These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28659986)

  • 21. Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
    Khalkhali M; Aram S; Zarrabi H; Kafie M; Heidarzadeh A
    Iran J Psychiatry; 2016 Apr; 11(2):104-14. PubMed ID: 27437007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
    Murphy TK; Brennan EM; Johnco C; Parker-Athill EC; Miladinovic B; Storch EA; Lewin AB
    J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):640-651. PubMed ID: 28358599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence.
    Couto JP; Moreira R
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():245-254. PubMed ID: 29908912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials.
    Eghdami S; Eissazade N; Heidari Mokarar M; Boroon M; Orsolini L; Shalbafan M
    Front Psychiatry; 2024; 15():1421150. PubMed ID: 39376972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of pre-supplementary motor area transcranial direct current stimulation for treatment resistant obsessive compulsive disorder: A randomized, double blinded, sham controlled trial.
    Gowda SM; Narayanaswamy JC; Hazari N; Bose A; Chhabra H; Balachander S; Bhaskarapillai B; Shivakumar V; Venkatasubramanian G; Reddy YCJ
    Brain Stimul; 2019; 12(4):922-929. PubMed ID: 30808612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial.
    Mowla A; Khajeian AM; Sahraian A; Chohedri AH; Kashkoli F
    CNS Spectr; 2010 Nov; 15(11):613-7. PubMed ID: 24726048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
    Jahanbakhsh SP; Manteghi AA; Emami SA; Mahyari S; Gholampour B; Mohammadpour AH; Sahebkar A
    Complement Ther Med; 2016 Aug; 27():25-9. PubMed ID: 27515872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo effect after prefrontal magnetic stimulation in the treatment of resistant obsessive-compulsive disorder: a randomized controlled trial.
    Mansur CG; Myczkowki ML; de Barros Cabral S; Sartorelli Mdo C; Bellini BB; Dias AM; Bernik MA; Marcolin MA
    Int J Neuropsychopharmacol; 2011 Nov; 14(10):1389-97. PubMed ID: 21557884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial.
    Shoja Shafti S; Kaviani H
    Ther Adv Psychopharmacol; 2015 Feb; 5(1):32-7. PubMed ID: 25653829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.
    Sharafkhah M; Aghakarim Alamdar M; Massoudifar A; Abdolrazaghnejad A; Ebrahimi-Monfared M; Saber R; Mohammadbeigi A
    Int Clin Psychopharmacol; 2019 Sep; 34(5):222-233. PubMed ID: 31058716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naproxen adjunct to fluoxetine for moderate-to-severe obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.
    Shamabadi A; Motavalian Z; Farahmand Y; Farahmand K; Arabzadeh Bahri R; Askari S; Ansari S; Fallahzadeh M; Shalbafan M; Akhondzadeh S
    Psychiatry Clin Neurosci; 2024 Oct; ():. PubMed ID: 39354696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
    Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
    JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study.
    Fux M; Benjamin J; Belmaker RH
    Int J Neuropsychopharmacol; 1999 Sep; 2(3):193-195. PubMed ID: 11281989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
    Stein DJ; Andersen EW; Tonnoir B; Fineberg N
    Curr Med Res Opin; 2007 Apr; 23(4):701-11. PubMed ID: 17407626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of atorvastatin on treatment-resistant obsessive-compulsive disorder: A double-blind randomized trial.
    Rahim F; Sayyah M
    Psychiatr Pol; 2018 Aug; 52(4):719-729. PubMed ID: 30368541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.